Professor of Medicine, University of Chicago Medicine
Hematology
Dr. Christopher K. Daugherty, MD
|
|
Give Review
Dr. Christopher K. Daugherty works in the field of Hematology. He graduated from Indiana University School of Medicine. Indiana University School of Medicine has a rank of 45 in research and a 47 in primary care He over the years received 4 awards: "CMS Meaningful Use Stage 1 Certification", "America's Top Doctors", "America's Top Doctors for Cancer" and "Super Doctor". Christopher Daugherty is a published doctor. He published 52 publications, including: 'Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: a pilot study.'
Publications
- The development of a financial toxicity patient-reported outcome in Cancer: The COST measure.
- When parents disclose BRCA1/2 test results: Their communication and perceptions of offspring response.
- Standards for palliative care delivery in oncology settings.
- Parent opinions regarding the genetic testing of minors for BRCA1/2.
- Physician preferences and knowledge gaps regarding the care of childhood Cancer survivors: a mailed survey of pediatric oncologists.
- An intervention to improve Cancer patients' understanding of early-phase clinical trials.
- What are terminally ill Cancer patients told about their expected deaths? A study of Cancer physicians' self-reports of prognosis disclosure.
- An international pilot study of oncology physicians' opinions and practices on Complementary and Alternative Medicine (CAM).
- Ethical, scientific, and regulatory perspectives regarding the use of placebos in Cancer clinical trials.
- Should genetic testing for BRCA1/2 be permitted for minors? Opinions of BRCA mutation carriers and their adult offspring.
- How often do BRCA mutation carriers tell their young children of the family's risk for Cancer? A study of parental disclosure of BRCA mutations to minors and young adu...
- Attitudes toward research participation and investigator conflicts of interest among advanced Cancer patients participating in early phase clinical trials.
- Housestaff and medical student attitudes toward medical errors and adverse events.
- Complementary and alternative medicine among advanced Cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision m...
- Are we taking without giving in return? The ethics of research-related biopsies and the benefits of clinical trial participation.
- Use of the internet to obtain Cancer information among Cancer patients at an urban county hospital.
- Ethical issues in phase I clinical trials.
- Examining ethical dilemmas as obstacles to hospice and palliative care for advanced Cancer patients.
- Overcoming obstacles to hospice care: an ethical examination of inertia and inaction.
- American oncologists' views of internet use by Cancer patients: a mail survey of American Society of Clinical Oncology members.
- The "cure" for Cancer: can the media report the hope without the hype?
- Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: a pilot study.
- Effect of X-irradiation dose rate on the clonagenic survival of human and experimental animal hematopoietic tumor Cell lines: evidence for heterogeneity.
- Hope and the limits of research.
- Prognostic factors for functional outcome of total knee replacement: a prospective study.
- Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic Cell transplantation.
- Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced Acute myeloid leukemia and myelodysplastic syndrome.
- Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic Cell transplantation.
- Learning from our patients: one participant's impact on clinical trial research and informed consent.
- High Dose Cytarabine and Mitoxantrone: An Effective Induction Regimen for High-Risk Acute Myeloid Leukemia (AML).
- Pushing the envelope: informed consent in phase I trials.
- Informed consent, the Cancer patient, and phase I clinical trials.
- Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin''s Disease and non-Hodgkin''s lymphoma.
- Psychosocial adjustment of patients and caregivers prior to allogeneic bone marrow transplantation.
- Referral and decision making among advanced Cancer patients participating in Phase I trials at a single institution.
- Impact of therapeutic research on informed consent and the ethics of clinical trials: a medical oncology perspective.
- Preliminary experience with a new chemotherapy regimen for adults with Acute lymphoblastic leukemia.
- A dose escalation study of total body irradiation followed by high-dose etoposide and allogeneic blood stem Cell transplantation for the treatment of advanced hematolo...
- Physician-determined patient risk of toxic effects: impact on enrollment and decision making in phase I Cancer trials.
- Perceptions of Cancer patients and their physicians involved in phase I trials.
- Study of cohort-specific consent and patient control in phase I Cancer trials.
- Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 advanced Cancer patients.
- Learning of your parent''s BRCA mutation during adolescence or early adulthood: a study of offspring experiences.
- Treatment of therapy-related Myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant.
- Oncologists'' and physiatrists'' attitudes regarding rehabilitation for patients with advanced Cancer.
- Associations among awareness of prognosis, hopefulness, and coping in patients with advanced Cancer participating in phase I clinical trials.
- ''Hitting you over the head'': oncologists'' disclosure of prognosis to advanced Cancer patients.
- Trusting God and medicine: spirituality in advanced Cancer patients volunteering for clinical trials of experimental agents.
- A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant Diseases.
- Ethical issues in the development of new agents.
- Psychological morbidities in adolescent and young adult blood Cancer patients during curative-intent therapy and early survivorship.
Schools
Indiana University School Of Medicine
Clarian Indiana University Hospital
University Of Chicago Hosps
Conditions Treated
- Acute Leukemia
- Anemia
- Chronic Myeloid Leukemia (CML)
- Colorectal Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- America's Top Doctors
- America's Top Doctors for Cancer
- Super Doctor
Education
-
University of Chicago -
Indiana University School of Medicine
Hospital
-
University of Chicago Medical Center
Drug Facts
| NPI NUMBER | 1063574523 | |
| NPPES Provider LastName | DAUGHERTY | |
| NPPES Provider FirstName | CHRISTOPHER | |
| NPPES Provider ZIPCode | 605276686 | |
| NPPES Provider State | IL | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 95.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 30.0 | |
| Percent Opioid Claims | 31.58 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1063574523 |
| Last Name Of The Provider | DAUGHERTY |
| First Name Of The Provider | CHRISTOPHER |
| View All |
Similar Doctors
|
|
Dr. Harvey M. Golomb, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James E. Hannigan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas F. Gajewski, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Richard L. Schilsky, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Everett E. Vokes, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Rita Nanda, MD |
|
|
Dr. Ezra E. Cohen, MD |